Altus's Phase III results for pancreatic enzyme therapy disappoint
This article was originally published in Scrip
Executive Summary
Altus Pharmaceuticals' Trizytek, an investigational treatment for pancreatic insufficiency in cystic fibrosis, has met its primary endpoint in a Phase III trial, but geographical differences in the results have disappointed investors.